Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 830-840

  Tsai, Min Shao ^a   Kuo, Ya Hsun ^a   Chiu, Yu Fan ^a   Su, Ying Chen ^a   Lin, Yun Wei ^a  

^a NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; COMPLEMENTARY DNA; CYCLOHEXIMIDE; DACTINOMYCIN; ERLOTINIB; GEMCITABINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; RAD51 PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; GENE CONSTRUCT; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RNA STABILITY;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RAD51 RECOMBINASE; RNA, SMALL INTERFERING; TRANSFECTION; UBIQUITIN;

EID: 78649550749     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173146     Document Type: Article

References (45)

1. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, and Schäfer H (2003) Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22:3243-3251.
2. Arnaudeau C, Helleday T, and Jenssen D (1999) The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. J Mol Biol 289:1231-1238.
3. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, and Testa JR (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25:2053-2059.
4. Bello VE, Aloyz RS, Christodoulopoulos G, and Panasci LC (2002) Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 63:1585-1588.
5. Bristow RG and Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180-192.
6. Brognard J, Clark AS, Ni Y, and Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997.
7. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, and Pouysségur J (1999) Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 18:664-674.
8. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B, and Bristow RG (2008) Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 68:605-614.
9. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, and Harari PM (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65:3328-3335.
10. Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, Kiltie AE, and Bristow RG (2009) Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 8:203-213.
11. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, and Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063.
12. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, and Brody AR (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10:6865-6871. (Pubitemid 39383035)
13. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, and Kaneda Y (2005) Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 7:1044-1052.
14. Janmaat ML, Kruyt FA, Rodriguez JA, and Giaccone G (2003) Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited anti-proliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316-2326.
15. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
16. Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, Lin ST, Chang CC, and Lin YW (2009) Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. Mol Cancer Res 7:1378-1389.
17. Koizumi K, Tanno S, Nakano Y, Habiro A, Izawa T, Mizukami Y, Okumura T, and Kohgo Y (2005) Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells. Anticancer Res 25:3347-3353.
18. Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, et al. (2005) Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 92:1711-1719.
19. Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B, Guaraldi M, Palomba G, Preti P, Petralia A, et al. (2005) Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41:81-92.
20. Matsumoto K, Nagahara T, Okano J, and Murawaki Y (2008) The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 20:863-872.
21. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3-9.
22. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966.
23. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, and Lawrence TS (2008) The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 14:5142-5149.
24. Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, Hahn EG, and Herold C (2007) bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 11:349-361.
25. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, and Kuwano M (2004) Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3:465-472.
26. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, et al. (2009) Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 8:45-54.
27. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, and Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87:227-253.
28. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S, and Stuerzbecher HW (2005) High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93:137-143.
29. Richardson C, Stark JM, Ommundsen M, and Jasin M (2004) Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 23:546-553.
30. Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, and Maestre J (2004) Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 10:4215s-4219s.
31. Sak A, Stueben G, Groneberg M, Böcker W, and Stuschke M (2005) Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br J Cancer 92:1089-1097.
32. Salomon DS, Brandt R, Ciardiello F, and Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
33. San Filippo J, Sung P, and Klein H (2008) Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77:229-257.
34. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, and Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
35. Schlessinger J (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110:669-672.
36. Shibata T, Kawano T, Nagayasu H, Okumura K, Arisue M, Hamada J, Takeichi N, and Hosokawa M (1996) Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 17:168-175.
37. Silvestri GA and Rivera MP (2005) Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128:3975-3984.
38. Silvestri GA and Spiro SG (2006) Carcinoma of the bronchus 60 years later. Thorax 61:1023-1028.
39. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, and Skorski T (2002) Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22:4189-4201.
40. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, and Skorski T (2001) BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8:795-806.
41. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, et al. (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13:2443-2449.
42. Veale D, Kerr N, Gibson GJ, Kelly PJ, and Harris AL (1993) The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68:162-165.
43. Vispé S, Cazaux C, Lesca C, and Defais M (1998) Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 26:2859-2864.
44. Wachters FM, van Putten JW, Maring JG, Zdzienicka MZ, Groen HJ, and Kampinga HH (2003) Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 57:553-562.
45. Wyman C and Kanaar R (2004) Homologous recombination: down to the wire. Curr Biol 14:R629-R631.